Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (2): 97-104.doi: 10.35541/cjd.20200802
• Guidelines and Consensus • Previous Articles Next Articles
Consensus Writing Group on the Diagnosis and Treatment of Acne Inversa/Hidradenitis Suppurativa in China
Received:
2020-08-14
Revised:
2020-12-20
Online:
2021-02-15
Published:
2021-01-29
Contact:
Wang Baoxi
E-mail:wangbx@vip.126.com
Consensus Writing Group on the Diagnosis and Treatment of Acne Inversa/Hidradenitis Suppurativa in China. Diagnosis and treatment of acne inversa/hidradenitis suppurativa in China: an expert consensus statement (2021 version)[J]. Chinese Journal of Dermatology, 2021, 54(2): 97-104.doi:10.35541/cjd.20200802
[1] | Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States[J]. J Am Acad Dermatol, 2013,68(3):412⁃419. doi: 10.1016/j.jaad.2012.07.027. |
[2] | Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem[J]. J Am Acad Dermatol, 2015,73(5 Suppl 1):S4⁃S7. doi: 10.1016/j.jaad.2015.07.052. |
[3] | Vinding GR, Miller IM, Zarchi K, et al. The prevalence of inverse recurrent suppuration: a population⁃based study of possible hidradenitis suppurativa[J]. Br J Dermatol, 2014,170(4):884⁃889. doi: 10.1111/bjd.12787. |
[4] | Garg A, Kirby JS, Lavian J, et al. Sex⁃ and age⁃adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States[J]. JAMA Dermatol, 2017,153(8):760⁃764. doi: 10.1001/jamadermatol.2017.0201. |
[5] | Napolitano M, Megna M, Timoshchuk EA, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment[J]. Clin Cosmet Investig Dermatol, 2017,10:105⁃115. doi: 10.2147/CCID.S111019. |
[6] | Lee JH, Kwon HS, Jung HM, et al. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population⁃based study[J]. J Eur Acad Dermatol Venereol, 2018,32(10):1784⁃1790. doi: 10.1111/jdv.15071. |
[7] | Yang JH, Moon J, Kye YC, et al. Demographic and clinical features of hidradenitis suppurativa in Korea[J]. J Dermatol, 2018,45(12):1389⁃1395. doi: 10.1111/1346⁃8138.14656. |
[8] | Kurokawa I, Hayashi N, Japan Acne Research Society. Questionnaire surveillance of hidradenitis suppurativa in Japan[J]. J Dermatol, 2015,42(7):747⁃749. doi: 10.1111/1346⁃8138. 12881. |
[9] | Wang B, Yang W, Wen W, et al. Gamma⁃secretase gene mutations in familial acne inversa[J]. Science, 2010,330(6007):1065. doi: 10.1126/science.1196284. |
[10] | Pink AE, Simpson MA, Desai N, et al. γ⁃Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis[J]. J Invest Dermatol, 2013,133(3):601⁃607. doi: 10.1038/jid. 2012.372. |
[11] | He Y, Xu H, Li C, et al. Nicastrin/miR⁃30a⁃3p/RAB31 axis regulates keratinocyte differentiation by impairing EGFR signaling in familial acne inversa[J]. J Invest Dermatol, 2019,139(1):124⁃134. doi: 10.1016/j.jid.2018.07.020. |
[12] | Kelly G, Hughes R, McGarry T, et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa[J]. Br J Dermatol, 2015,173(6):1431⁃1439. doi: 10. 1111/bjd.14075. |
[13] | Witte⁃Händel E, Wolk K, Tsaousi A, et al. The IL⁃1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction[J]. J Invest Dermatol, 2019,139(6):1294⁃1305. doi: 10.1016/j.jid.2018.11.018. |
[14] | Thomi R, Cazzaniga S, Seyed Jafari SM, et al. Association of hidradenitis suppurativa with T helper 1/T helper 17 phenotypes: a semantic map analysis[J]. JAMA Dermatol, 2018,154(5):592⁃595. doi: 10.1001/jamadermatol.2018.0141. |
[15] | Hotz C, Boniotto M, Guguin A, et al. Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa[J]. J Invest Dermatol, 2016,136(9):1768⁃1780. doi: 10.1016/j.jid.2016.04.036. |
[16] | Xu H, He Y, Hui Y, et al. NCSTN mutations in hidradenitis suppurativa/acne inversa do not influence cytokine production by peripheral blood mononuclear cells[J]. Br J Dermatol, 2017,176(1):277⁃279. doi: 10.1111/bjd.15076. |
[17] | Byrd AS, Carmona⁃Rivera C, O′Neil LJ, et al. Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa[J]. Sci Transl Med, 2019,11(508):eaav5908. doi: 10.1126/scitranslmed.aav5908. |
[18] | Kanni T, Zenker O, Habel M, et al. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?[J]. Br J Dermatol, 2018,179(2):413⁃419. doi: 10.1111/bjd.16428. |
[19] | Giamarellos⁃Bourboulis EJ, Argyropoulou M, Kanni T, et al. Clinical efficacy of complement C5a inhibition by IFX⁃1 in hidradenitis suppurativa: an open⁃label single⁃arm trial in patients not eligible for adalimumab[J]. Br J Dermatol, 2020,183(1):176⁃178. doi: 10.1111/bjd.18877. |
[20] | Ring HC, Thorsen J, Saunte DM, et al. The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls[J]. JAMA Dermatol, 2017,153(9):897⁃905. doi: 10.1001/jamadermatol.2017.0904. |
[21] | Ring HC, Bay L, Nilsson M, et al. Bacterial biofilm in chronic lesions of hidradenitis suppurativa[J]. Br J Dermatol, 2017,176(4):993⁃1000. doi: 10.1111/bjd.15007. |
[22] | Ring HC, Emtestam L. The microbiology of hidradenitis suppurativa[J]. Dermatol Clin, 2016,34(1):29⁃35. doi: 10.1016/j.det.2015.08.010. |
[23] | Lyons AB, Shabeeb N, Nicholson CL, et al. Emerging medical treatments for hidradenitis suppurativa[J]. J Am Acad Dermatol, 2020,83(2):554⁃562. doi: 10.1016/j.jaad.2020.04.009. |
[24] | Nazary M, van der Zee HH, Prens EP, et al. Pathogenesis and pharmacotherapy of hidradenitis suppurativa[J]. Eur J Pharmacol, 2011,672(1⁃3):1⁃8. doi: 10.1016/j.ejphar.2011.08. 047. |
[25] | Kurzen H, Kurokawa I, Jemec GB, et al. What causes hidradenitis suppurativa?[J]. Exp Dermatol, 2008,17(5):455⁃472. doi: 10.1111/j.1600⁃0625.2008.00712_ 1.x. |
[26] | van der Zee HH, Jemec GB. New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes[J]. J Am Acad Dermatol, 2015,73(5 Suppl 1):S23⁃S26. doi: 10.1016/j.jaad.2015.07.047. |
[27] | Lu L, Lai H, Pan Z, et al. Clinical and histopathological characteristics in patients with scarring folliculitis type of acne inversa[J]. Dermatoendocrinol, 2017,9(1):e1361575. doi: 10. 1080/19381980.2017.1361575. |
[28] | Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa[J]. J Eur Acad Dermatol Venereol, 2015,29(4):619⁃644. doi: 10.1111/jdv.12966. |
[29] | Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management[J]. J Am Acad Dermatol, 2019,81(1):76⁃90. doi: 10.1016/j.jaad.2019.02. 067. |
[30] | Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach[M]//Roenigh R, Roenigh H. Dermatologic Surgery. New York: Marcel Dekker, 1989:729⁃739. |
[31] | Sartorius K, Lapins J, Emtestam L, et al. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa[J]. Br J Dermatol, 2003,149(1):211⁃213. doi: 10.1046/j.1365⁃2133.2003.05390.x. |
[32] | Sartorius K, Emtestam L, Jemec GB, et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity[J]. Br J Dermatol, 2009,161(4):831⁃839. doi: 10. 1111/j.1365⁃2133.2009.09198.x. |
[33] | Hessam S, Scholl L, Sand M, et al. A novel severity assessment scoring system for hidradenitis suppurativa[J]. JAMA Dermatol, 2018,154(3):330⁃335. doi: 10.1001/jamadermatol.2017.5890. |
[34] | Amano M, Grant A, Kerdel FA. A prospective open⁃label clinical trial of adalimumab for the treatment of hidradenitis suppurativa[J]. Int J Dermatol, 2010,49(8):950⁃955. doi: 10. 1111/j.1365⁃4632.2010.04545.x. |
[35] | Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double⁃blind, placebo⁃controlled crossover trial[J]. J Am Acad Dermatol, 2010,62(2):205⁃217. doi: 10.1016/j.jaad. 2009.06.050. |
[36] | Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (hidradenitis suppurativa clinical response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo⁃controlled portion of a phase 2 adalimumab study[J]. J Eur Acad Dermatol Venereol, 2016,30(6):989⁃994. doi: 10.1111/jdv.13216. |
[37] | Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity[J]. Br J Dermatol, 2017,177(5):1401⁃1409. doi: 10. 1111/bjd.15748. |
[38] | Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial[J]. Ann Intern Med, 2012,157(12):846⁃855. doi: 10.7326/0003⁃4819⁃157⁃12⁃201212180⁃00004. |
[39] | Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018[J]. Br J Dermatol, 2019,180(5):1009⁃1017. doi: 10.1111/bjd.17537. |
[40] | Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management[J]. J Am Acad Dermatol, 2019,81(1):91⁃101. doi: 10.1016/j.jaad.2019.02.068. |
[41] | Zouboulis CC, Bechara FG, Dickinson⁃Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization ⁃ systematic review and recommendations from the HS ALLIANCE working group[J]. J Eur Acad Dermatol Venereol, 2019,33(1):19⁃31. doi: 10.1111/jdv.15233. |
[42] | Gulliver W, Landells I, Morgan D, et al. Hidradenitis suppurativa: a novel model of care and an integrative strategy to adopt an orphan disease[J]. J Cutan Med Surg, 2018,22(1):71⁃77. doi: 10.1177/1203475417736290. |
[43] | Alavi A, Lynde C, Alhusayen R, et al. Approach to the management of patients with hidradenitis suppurativa: a consensus document[J]. J Cutan Med Surg, 2017,21(6):513⁃524. doi: 10.1177/1203475417716117. |
[44] | Gulliver W, Zouboulis CC, Prens E, et al. Evidence⁃based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa[J]. Rev Endocr Metab Disord, 2016,17(3):343⁃351. doi: 10.1007/s11154⁃016⁃9328⁃5. |
[45] | Hunger RE, Laffitte E, Läuchli S, et al. Swiss practice recommendations for the management of hidradenitis suppurativa/acne inversa[J]. Dermatology, 2017,233(2⁃3):113⁃119. doi: 10.1159/000477459. |
[46] | Magalhães RF, Rivitti⁃Machado MC, Duarte GV, et al. Consensus on the treatment of hidradenitis suppurativa ⁃ Brazilian Society of Dermatology[J]. An Bras Dermatol, 2019,94(2 Suppl 1):7⁃19. doi: 10.1590/abd1806⁃4841.20198607. |
[47] | Braunberger TL, Nartker NT, Nicholson CL, et al. Ertapenem ⁃ a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa[J]. Int J Dermatol, 2018,57(9):1088⁃1093. doi: 10.1111/ijd.14036. |
[48] | Maarouf M, Clark AK, Lee DE, et al. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials[J]. J Dermatolog Treat, 2018,29(5):441⁃449. doi: 10.1080/09546634.2017.1395806. |
[49] | Miller I, Lynggaard CD, Lophaven S, et al. A double⁃blind placebo⁃controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa[J]. Br J Dermatol, 2011,165(2):391⁃398. doi: 10.1111/j.1365⁃2133.2011.10339.x. |
[50] | Poveda I, Vilarrasa E, Martorell A, et al. Serum zinc levels in hidradenitis suppurativa: a case⁃control study[J]. Am J Clin Dermatol, 2018,19(5):771⁃777. doi: 10.1007/s40257⁃018⁃0374⁃5. |
[51] | Hotz C, Sbidian E, Ingen⁃Housz⁃Oro S, et al. Thalidomide in severe hidradenitis suppurativa: a therapeutic option[J]. Acta Derm Venereol, 2019,99(12):1170⁃1171. doi: 10.2340/00015 555⁃3268. |
[52] | Iwasaki J, Marra DE, Fincher EF, et al. Treatment of hidradenitis suppurativa with a nonablative radiofrequency device[J]. Dermatol Surg, 2008,34(1):114⁃117. doi: 10.1111/j.1524⁃4725.2007.34025.x. |
[53] | Wilden S, Friis M, Tuettenberg A, et al. Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF)[J/OL]. J Dermatolog Treat, 2019:1⁃8(2019⁃10⁃17). doi: 10.1080/09546634.2019.1677842. https://www.tandfonline.com/doi/full/10.1080/09546634.2019.1677842. |
[54] | Mahmoud BH, Tierney E, Hexsel CL, et al. Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long⁃pulsed neodymium:yttrium⁃aluminium⁃garnet laser[J]. J Am Acad Dermatol, 2010,62(4):637⁃645. doi: 10.1016/j.jaad.2009.07.048. |
[55] | Mordon S. Treating hidradenitis suppurativa with photodynamic therapy[J]. J Cosmet Laser Ther, 2018,20(4):223⁃228. doi: 10. 1080/14764172.2017.1400169. |
[56] | Emtestam L, Lapins J, Sartorius K. Carbon dioxide laser treatment using methylene blue⁃assisted sinus tract identification in hidradenitis suppurativa[J]. Dermatol Surg, 2017,43(4):604⁃605. doi: 10.1097/DSS.0000000000001068. |
[57] | Vekic DA, Cains GD. Hidradenitis suppurativa ⁃ management, comorbidities and monitoring[J]. Aust Fam Physician, 2017,46(8):584⁃588. |
[1] | Chinese Society of Dermatology, China Dermatologist Association, Chinese Association of Integrative Medicine Board of Dermatovenereology. Expert consensus on the clinical application of chemical peeling in China (2024 public version) [J]. Chinese Journal of Dermatology, 2024, 0(5): 20230620-e20230620. |
[2] | Writing Committee Expert Group on “Treatment of Extramammary Paget′s Disease: a Chinese Expert Consensus Statement ()”. Treatment of extramammary Paget′s disease: a Chinese expert consensus statement (2024) [J]. Chinese Journal of Dermatology, 2024, 57(5): 400-408. |
[3] | China Dermatologist Association. Guidelines for the management of chronic pruritus (2024) [J]. Chinese Journal of Dermatology, 2024, 57(5): 387-399. |
[4] | Mycobacteriosis Research Group, China “Belt and Road” Dermatology Alliance, Division of Dermatology and STI Diagnosis, Chinese Association on Leprosy. Expert consensus on the clinical diagnosis and treatment of cutaneous tuberculosis in China (2024) [J]. Chinese Journal of Dermatology, 2024, 57(5): 426-434. |
[5] | China Dermatologist Association, Combination of Traditional and Western Medicine Dermatology. Diagnosis and treatment of erythrodermic psoriasis: a Chinese expert consensus statement (2024) [J]. Chinese Journal of Dermatology, 2024, 57(5): 409-417. |
[6] | Mycology Group, Combination of Traditional and Western Medicine Dermatology, Chinese Antifungal-Resistant Dermatophytosis Expert Consensus Group. Expert consensus on the diagnosis, treatment, prevention and control of antifungal-resistant dermatophyte infections in China (2024) [J]. Chinese Journal of Dermatology, 2024, 57(5): 418-425. |
[7] | Yue Shuzhen, Shu Ye, Luo Yangyang, Li Keyao, Zhang Yuanyuan, Tang Jianping, Wei Zhu. Efficacy and safety of omalizumab in the treatment of chronic urticaria in children: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(4): 354-358. |
[8] | Liu Yi, Qu Ying, Lei Wenzhi, Liu Xiaogang, Pan Weihua, Zhang Chao. Clinical efficacy of salt-packing therapy in the treatment of pyogenic granuloma [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230553-e20230553. |
[9] | Zhang Dimin, Cao Cheng, Zhou Miaoni, Sheng Anqi, Lin Fuquan, Xu Ai′e. Analysis of disease control rate and its influencing factors in patients with progressive non-segmental vitiligo after combined treatment with compound betamethasone injection [J]. Chinese Journal of Dermatology, 2024, 57(4): 350-354. |
[10] | He Yanyan, Ma Xiao, Hui Yun, Wang Wenzhu, Wang Baoxi, Zeng Rong, Xu Haoxiang, . Role of peroxisome proliferator-activated receptor signaling pathway in acne inversa by high-throughput sequencing: a preliminary study [J]. Chinese Journal of Dermatology, 2024, 57(4): 309-315. |
[11] | Wang Yimeng, Wu Wenting, Zhang Qian, Zhang Chunlei, Li Weiwei. Clinical and pathological diagnoses of 389 patients with primary solid tumors localized in the perianal and external genitalia regions [J]. Chinese Journal of Dermatology, 2024, 57(4): 316-323. |
[12] | Ge Xinhong, Ma Yingdong, Jiao Yaning, Liu Lingling, Zhou Mei, Zi Wei, Li Bowen. Analysis of efficacy and safety of 532-nm picosecond laser in the treatment of early-stage facial seborrheic keratosis [J]. Chinese Journal of Dermatology, 2024, 57(4): 359-362. |
[13] | Yan Rufan, Liao Jieyue, Guo Ziyu, Yao Nan, Zhou Wenyu, Luo Shuaihantian, Zhang Guiying, Zhao Ming. Pathogenesis and targeted therapy of pemphigus [J]. Chinese Journal of Dermatology, 2024, 57(4): 374-378. |
[14] | Dai Yeqin, Song Xiuzu. Application of hair follicle transplantation and follicular cell suspension transplantation in the treatment of vitiligo [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230274-e0230274. |
[15] | Chen Lixin, Wang Ying, Gao Xibo, Qin Bei, Li Qinfeng. Features of classic verruca plana & hypopigmented verruca plana in reflectance confocal microscopy [J]. Chinese Journal of Dermatology, 2024, 57(3): 249-253. |
|